How the Availability of Capital Impacts the Role of the CMO

At the May 2015 Chief Medical Officer’s Summit in Boston, we featured a session on: How the Availability of Capital Impacts the Role of the CMO In this session, the panelists cover: Optimal use of the proceeds Determining a development path, new molecules vs. new studies on the same molecules Appropriate stewardship of the capital Balancing short-term and long-term objectives; particularly when they may conflict Concerns and/or benefits of early financing without having reached clinical goals Examining the new threshold in moving development forward How is the progress in the industry translating into new drug discovery? Maintaining the same rigor for investment Moderated by: Louis Brenner, MD Chief Operating Officer, Allena Pharmaceuticals Panelists: Raj Malik, MD CMO, G1 Therapeutics Jim Roach, MD CMO and SVP, Development, Momenta Pharmaceuticals Oliver Rosen, MD CMO, Deciphera Pharmaceuticals Ian Walters, MD VP and CMO, Intensity Therapeutics The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to: 1. Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits. 2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support. For information, visit www.theconferenceforum.org Partial and full scholarships available for start-ups.